Tokyo, Jan. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060324) titled 'Clinical results of SERM in the treatment of osteoporosis' on Jan. 12.
Study Type:
Observational
Primary Sponsor:
Institute - Niimi orthopaedics clinic
Condition:
Condition - Osteoporosis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the treatment outcomes of SERM in real-world clinical practice.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 30
years-old
<=
Age-upper limit - Not applicable
Gender - Female
Key inclusion criteria - Osteoporosis
Key exclusion criteria - 1)a history of venous thromboembolism (VTE) or a high risk of thromboembolic events
2)prolonged immobilization
3)pregnancy, suspected pregnancy, or breastfeeding
4)a history of hypersensitivity to the study drug or its components
5)failure to obtain written informed consent for participation in the study
Target Size - 1000
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2018 Year 01 Month 01 Day
Date of IRB - 2025 Year 12 Month 01 Day
Anticipated trial start date - 2018 Year 08 Month 01 Day
Last follow-up date - 2035 Year 12 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069004
Disclaimer: Curated by HT Syndication.
